Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug

PainReform Ltd. shares surged 70% following its DeepSolar unit's inclusion in the NVIDIA Connect Program, which grants access to AI frameworks for advanced solar forecasting. Concurrently, Iovance Biotherapeutics Inc. rose over 12% as its melanoma treatment, Amtagvi, received conditional Health Canada approval, building on its U.S. market presence and $54.1 million in Q2 2025 U.S. sales. Separately, Aldeyra Therapeutics and Altimmune Inc. secured FDA Fast Track designations for their respective drug candidates, ADX-2191 and Pemvidutide, while Delcath Systems and OS Therapies reported progress in their oncology clinical trials, highlighting ongoing pipeline advancements across the small-cap biotech and cleantech sectors.

Analysis

The market is demonstrating strong positive reactions to tangible value-creation events in the small-cap biotech and technology sectors. PainReform Ltd. (PRFX) experienced a significant 70% valuation increase after its solar energy unit was accepted into the NVIDIA Connect Program, a partnership that provides critical AI development resources and lends significant credibility to its DeepSolar platform. Similarly, Iovance Biotherapeutics (IOVA) saw a 12% rise upon receiving conditional Health Canada approval for its melanoma drug, Amtagvi; this event expands its commercial footprint beyond the U.S., where the drug already generated $54.1 million in Q2 2025 sales, providing a concrete revenue baseline for growth. In contrast, regulatory process milestones yielded mixed results. While Altimmune (ALT) gained over 5% after its drug candidate received FDA Fast Track designation, Aldeyra Therapeutics (ALDX) declined 1% despite securing the same designation for its drug, suggesting the market is either discounting the news or weighing other company-specific factors. Earlier-stage clinical progress showed more muted impact, with Delcath Systems (DCTH) moving just over 1% on the dosing of a first patient in a trial with data not expected until 2028, while OS Therapies (OSTX) saw a minor gain on its stated plan to submit a BLA in late Q3 2025, contingent on a successful FDA meeting in August.

Key Decisions for Investors

• Given the substantial 70% rally in PainReform (PRFX), investors should now focus on the company's ability to translate the NVIDIA partnership into tangible technological and commercial milestones for its DeepSolar unit.
• For Iovance (IOVA), the key consideration is commercial execution; monitor upcoming quarterly earnings for the sales trajectory of Amtagvi in both the U.S. and the new Canadian market to validate its growth story.
• The diverging stock reactions for Aldeyra (ALDX) and Altimmune (ALT) on similar FDA news suggest investors should treat regulatory milestones on a case-by-case basis, scrutinizing underlying factors before committing capital.
• Investors in Delcath (DCTH) should be prepared for a long holding period, as meaningful data is not due until 2028, whereas OS Therapies (OSTX) presents a clear near-term catalyst with its scheduled FDA meeting on August 27, 2025, which will dictate its path forward.